bioRxivCancer Biology
Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem Cells
A. K. Singh, A. Verma, A. Singh, R. K. Arya, S. Maheshwari, P. Chaturvedi, M. A. Nengroo, K. K. Saini, A. L. Vishwakarma, K. Singh, J. Sarkar, D. Datta
Abstract
Drug resistance is one of the trademark features of Cancer Stem Cells (CSCs). We and others have recently shown that paucity of functional death receptors (DR4/5) on the cell surface of tumor cells is one of the major reasons for drug resistance, but their involvement in the context of in CSCs is poorly understood. By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs. Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs. Concurrently, EZH2 knockdown demonstrated increased expression of DR4/DR5, significant reduction of CSC phenotype such as spheroid formation in-vitro and tumorigenic potential in-vivo in colon cancer. TCGA data analysis of human colon cancer clinical samples shows strong inverse correlation between EZH2 and DR4. Taken together, this study provides an insight about epigenetic regulation of DR4 in colon CSCs and advocates that drug resistant colon cancer can be therapeutically targeted by combining TRAIL and small molecule EZH2 inhibitors.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A switch from histone methyltransferase-EZH2 to demethylase KDM6A activity marks reinitiation of proliferation of drug treated colorectal cancer cells
Subhashree Chatterjee, Ritika Jaiswal, … Rajdeep Chowdhury·bioRxiv·Nov 4, 2025
- The E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance to irinotecan (CPT-11).
Junichi Matsubara, Yong Fuga Li, … Piero D. Dalerba·bioRxiv·Jan 22, 2025
- Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination
Noemi Arrighetti, Cesare Soffientini, … Sandro Pasquali·bioRxiv·Aug 4, 2026
- Modification of Death receptor-mediated cell death in osteosarcoma cell lines using epigenetic modifiers
Habitha Sri Prabhakaran, Neil Alan Cross·bioRxiv·Dec 13, 2025
- Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target
Edmond F. O’Donnell, Maria Muñoz, … Janai R. Carr·npj Precision OncologyPeer-reviewed·Jan 9, 2025
- A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress
Y. LIAO, C.-H. Chen, … K. Xu·bioRxiv·Sep 11, 2020